Cancer Dependency Map Analytics | Cancer, Ageing and Somatic Mutation
Cancer Dependency Map Analytics
Wellcome Sanger Institute, Genome Research Limited
Cancer Dependency Map Analytics at Sanger Institute
Our Research and Approach
We design algorithms and computational tools for the analysis of large-scale cancer pharmacogenomics and functional genomics datasets (from chemical and genome-editing screens) to the aim of identifiying new oncology therapeutic targets and markers of gene-essentiality/drug-response.
In partnership with Open Targets, we provide computational support and analytic solutions to the international Cancer Dependency Map consortium, and to other projects engaged in the analysis of data from large-scale chemo/genetic screens.
Francesco is responsible for the design of analytical methods and software, and the management of day-by-day operations to deliver scientific milestones toward the definition of a global Cancer Dependency Map: an atlas of genetic dependencies and vulnerabilities, at an individual cancer cell resolution, which could be exploited for the development of cancer targeted and personalized therapies.
The Cancer Dependency Map integrates the work of multiple experimental and computational research project at the Sanger Institute with the shared aim of identifying dependencies in cancer cells which could be exploited to develop new therapies. This knowledge is foundational for our understanding of cancer biology and the development of precision cancer medicine.
The Cancer, Ageing and Somatic Mutation Programme seeks to provide leadership in data aggregation and informatics innovation, developing high-throughput cellular models of cancer for genome-wide functional screens and drug testing, and exploring basic scientific questions about the role somatic mutation plays in clonal evolution, ageing and development.
We are a team of cancer biologists, geneticists and computational biologists interested in understanding how cancers develop and the ways of controlling their growth. We work on a range of malignancies but are particularly interested in melanoma and other skin cancers.
Our goal is to understand how genetic background influences outcome of mutations. To do so, we measure, model, and modulate cell state across healthy and disease-relevant human genetic diversity. In the lab, we develop tools for genetic perturbations, and use genome engineering and synthetic biology to create cell lines for screening cellular traits. In the office, we develop probabilistic models as well as software tools to accurately and efficiently analyse the readouts.
Open Targets is a pioneering public-private partnership between Biogen, Celgene, EMBL-EBI, GlaxoSmithKline (GSK), Takeda, and the Wellcome Sanger Institute and is located on the Wellcome Genome Campus. Open Targets brings together expertise from six complementary institutions to systematically identify and prioritise targets from which safe and effective medicines can be developed, to help others find good targets, and to get those targets adopted into drug discovery pipelines.
Current focuses are oncology, immunology and neurodegeneration through an R&D framework that can be applied to all aspects of human disease.